Literature DB >> 16741760

Which radionuclides will nuclear oncology need tomorrow?

Jacques Barbet, Jean-François Chatal, François Gauché, Jacques Martino.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16741760     DOI： 10.1007/s00259-006-0116-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  18 in total

1.  Immuno-PET for tumor targeting.

Authors:  Fook T Lee; Andrew M Scott
Journal:  J Nucl Med       Date:  2003-08       Impact factor: 10.057

Review 2.  The promise of immuno-PET in radioimmunotherapy.

Authors:  Iris Verel; Gerard W M Visser; Guus A van Dongen
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

3.  Radioimmunotherapy, a new breakthrough in the treatment of follicular non-Hodgkin's lymphoma: the European perspective.

Authors:  Jean-François Chatal
Journal:  Cancer Biother Radiopharm       Date:  2006-02       Impact factor: 3.099

4.  Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.

Authors:  Marion de Jong; Wout A P Breeman; Roelf Valkema; Bert F Bernard; Eric P Krenning
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

5.  Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma.

Authors:  C G Moertel; J A Hanley; L A Johnson
Journal:  N Engl J Med       Date:  1980-11-20       Impact factor: 91.245

Review 6.  Cancer radioimmunotherapy with alpha-emitting nuclides.

Authors:  Olivier Couturier; Stéphane Supiot; Marie Degraef-Mougin; Alain Faivre-Chauvet; Thomas Carlier; Jean-François Chatal; François Davodeau; Michel Cherel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05       Impact factor: 9.236

7.  Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma.

Authors:  G L DeNardo; S J DeNardo; R T O'Donnell; L A Kroger; D L Kukis; C F Meares; D S Goldstein; S Shen
Journal:  Clin Lymphoma       Date:  2000-09

Review 8.  Fluorinated tracers for imaging cancer with positron emission tomography.

Authors:  Olivier Couturier; André Luxen; Jean-François Chatal; Jean-Philippe Vuillez; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

9.  Targeted alpha particle immunotherapy for myeloid leukemia.

Authors:  Joseph G Jurcic; Steven M Larson; George Sgouros; Michael R McDevitt; Ronald D Finn; Chaitanya R Divgi; Ase M Ballangrud; Klaus A Hamacher; Dangshe Ma; John L Humm; Martin W Brechbiel; Roger Molinet; David A Scheinberg
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

10.  Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma.

Authors:  C G Moertel; M Lefkopoulo; S Lipsitz; R G Hahn; D Klaassen
Journal:  N Engl J Med       Date:  1992-02-20       Impact factor: 91.245
View more
  5 in total

1.  Nothing new under the nuclear sun: towards 80 years of theranostics in nuclear medicine.

Authors:  Frederik A Verburg; Alexander Heinzel; Heribert Hänscheid; Felix M Mottaghy; Markus Luster; Luca Giovanella
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-06       Impact factor: 9.236

2.  ARRONAX, a high-energy and high-intensity cyclotron for nuclear medicine.

Authors:  Ferid Haddad; Ludovic Ferrer; Arnaud Guertin; Thomas Carlier; Nathalie Michel; Jacques Barbet; Jean-François Chatal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-09       Impact factor: 9.236

Review 3.  Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.

Authors:  C Andrew Boswell; Martin W Brechbiel
Journal:  Nucl Med Biol       Date:  2007-06-08       Impact factor: 2.408

Review 4.  Astatine-211: production and availability.

Authors:  Michael R Zalutsky; Marek Pruszynski
Journal:  Curr Radiopharm       Date:  2011-07

5.  (124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy.

Authors:  Bernard M Tijink; Lars R Perk; Marianne Budde; Marijke Stigter-van Walsum; Gerard W M Visser; Reina W Kloet; Ludger M Dinkelborg; C René Leemans; Dario Neri; Guus A M S van Dongen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-04       Impact factor: 9.236
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.